心血管事件风险测试2评分在血液透析合并终末期肾病患者中的预测性能
本研究整合AURORA试验2311例与4D试验1137例血液透析的ESKD患者数据,按预设脂质比值四分位分层计算CERT2评分。校正传统心血管因素后,最高风险组较低风险组主要不良心血管事件风险约高两倍(AURORA HR 1.98,95%CI 1.53-2.55;4D HR 1.70,95%CI 1.23-2.34),全因死亡风险亦约高两倍。CERT2预测性能优于LDL胆固醇等传统标志物及现有风险评分。
要点
- CERT2评分可对血液透析ESKD患者进行主要不良心血管事件、心血管死亡和全因死亡的风险分层。
- 最高CERT2风险类别患者的主要不良心血管事件和全因死亡风险约为最低类别的两倍。
- CERT2作为基于脂质的生物标志物方案,在透析患者中预测性能优于常规心血管风险标志物和现有风险评分。
核心结论
- CERT2风险评分可识别血液透析ESKD患者中主要不良心血管事件和全因死亡风险较高的个体。
- CERT2评分作为新型脂质生物标志物,在血液透析患者心血管风险分层中优于现有生物标志物和风险评分。
研究设计与样本
- 本研究整合AURORA试验2311例与4D试验1137例接受血液透析的ESKD患者数据。
- CERT2风险评分基于所有参与者预设脂质比值的四分位分层计算。
- 主要结局为主要不良心血管事件,附加结局为心血管死亡和全因死亡。
主要发现
- 校正传统心血管因素及其他变量后,最高风险类别较最低类别主要不良心血管事件风险约高两倍(AURORA:HR 1.98,95%CI 1.53-2.55;4D:HR 1.70,95%CI 1.23-2.34)。
- 最高风险类别较最低类别全因死亡风险亦约高两倍(AURORA:HR 2.14,95%CI 1.72-2.66;4D:HR 1.78,95%CI 1.36-2.34)。
- 两项试验中CERT2风险评分预测性能均优于LDL胆固醇等传统标志物。
- AURORA队列中CERT2风险评分在预测心血管结局方面优于Systematic Coronary Risk Evaluation 2和动脉粥样硬化性心血管疾病风险评估工具。
临床怎么用
- 可考虑将CERT2风险评分用于血液透析ESKD患者的心血管风险分层,识别高风险个体。
- CERT2评分基于脂质比值,可能为透析患者提供优于传统血脂标志物的预后评估工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: The Cardiovascular Event Risk Test 2 (CERT2) risk score effectively stratified patients undergoing hemodialysis patients on the basis of their risk of major adverse cardiovascular (CV) event, CV death, and all-cause death. Patients in the highest CERT2 risk category had a two-fold higher risk of major adverse CV event and all-cause death compared with those in the lowest category. CERT2 risk score shows that novel lipid-based biomarker solution outperforms regular CV risk biomarkers and existing risk scores in dialysis. BACKGROUND: ESKD is closely associated with cardiovascular disease (CVD) primarily because of shared underlying conditions, such as diabetes mellitus and hypertension. Increased levels of circulating ceramide lipids have been linked to major adverse events in CVD, as well as to ESKD. Our aim was to investigate the predictive value of the Cardiovascular Event Risk Test 2 (CERT2) risk score in patients with ESKD in identifying patients at an increased risk of major adverse cardiovascular events (MACEs). METHODS: This study combines data from 2311 patients from the A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial and 1137 patients from the Die Deutsche Diabetes Dialyze Studie (4D) trial. Both studies enrolled patients with ESKD undergoing hemodialysis. The CERT2 risk score has been calculated on the basis of quartile stratification of predefined lipid ratios for all the participants. The primary outcome of interest was MACE with additional outcomes of cardiovascular death and all-cause death. RESULTS: After adjusting for traditional CV factors and other variables, two-fold higher risk was reported for MACE for patients in the highest risk category (AURORA: hazard ratios [HRs], 1.98; 95% confidence interval [CI], 1.53 to 2.55; 4D: HR, 1.70; 95% CI, 1.23 to 2.34) in comparison with those in the lowest risk category. Similarly, the two-fold higher risk was also observed for all-cause death for patients in the highest risk category (AURORA: HR, 2.14; 95% CI, 1.72 to 2.66; 4D: HR, 1.78; 95% CI, 1.36 to 2.34). In both trials, the CERT2 risk score demonstrated superior predictive performance compared with traditional markers like LDL cholesterol. In the AURORA cohort, the CERT2 risk score outperformed Systematic Coronary Risk Evaluation 2 and atherosclerotic CVD risk estimators in predicting CV outcomes. CONCLUSIONS: The CERT2 risk score identifies patients with ESKD who are at a higher risk of MACE and all-cause death. These findings highlight the potential of the CERT2 risk score as a novel lipid-based biomarker for CV risk stratification in patients undergoing hemodialysis, offering improved prognostic performance over existing biomarkers and risk scores.
引用
- Witoslawska A, Drechsler C, Duarte K, et al. Predictive Performance of the Cardiovascular Event Risk Test 2 Risk Score in Hemodialysis Patients with ESKD. Clin J Am Soc Nephrol. 2025. PMID: 41370127. doi:10.2215/CJN.0000000831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。